Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KLK5 | Q9Y337 | 3/20 | 0.63 |
| ▸ | PSEN1 | P49768 | 3/20 | 0.49 |
| ▸ | PSEN2 | P49810 | 3/20 | 0.49 |
| ▸ | APH1B | Q8WW43 | 3/20 | 0.49 |
| ▸ | NCSTN | Q92542 | 3/20 | 0.49 |
| ▸ | APH1A | Q96BI3 | 3/20 | 0.49 |
| ▸ | PSENEN | Q9NZ42 | 3/20 | 0.49 |
| ▸ | REN | P00797 | 8/20 | 0.49 |
| ▸ | APP | P05067 | 1/20 | 0.49 |
| ▸ | ATM | Q13315 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6653213 | 0.87 | KLK5 (0.68) | KLK5PSEN1PSEN2APH1BNCSTN | |
| SCHEMBL10606303 | 0.87 | KLK5 (0.68) | KLK5PSEN1PSEN2APH1BNCSTN | |
| SCHEMBL6876159 | 0.87 | KLK5 (0.68) | KLK5PSEN1PSEN2APH1BNCSTN | |
| SCHEMBL9833378 | 0.85 | KLK5 (0.72) | KLK5PSEN1PSEN2APH1BNCSTN | |
| SCHEMBL9482833 | 0.85 | KLK5 (0.72) | KLK5PSEN1PSEN2APH1BNCSTN | |
| SCHEMBL5831798 | 0.83 | KLK5 (0.50) | KLK5PSEN1PSEN2APH1BNCSTN | |
| SCHEMBL9832414 | 0.83 | KLK5 (0.71) | KLK5PSEN1PSEN2APH1BNCSTN | |
| SCHEMBL6873021 | 0.83 | KLK5 (0.71) | KLK5PSEN1PSEN2APH1BNCSTN | |
| SCHEMBL8787243 | 0.83 | KLK5 (0.71) | KLK5PSEN1PSEN2APH1BNCSTN | |
| SCHEMBL9815894 | 0.83 | KLK5 (0.71) | KLK5PSEN1PSEN2APH1BNCSTN |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2089416-B1 | DEPSIPEPTIDES AND THEIR THERAPEUTIC USE | UNIV SOUTHAMPTON (GB) | 2014-02-26 | — | — | EP | disclosed |
| US-8247372-B2 | Depsipeptides and their therapeutic use | UNIVERSITY OF SOUTHAMPTON (GB) | 2012-08-21 | — | — | US | disclosed |
| US-8247372-B2 | Depsipeptides and their therapeutic use | UNIVERSITY OF SOUTHAMPTON (GB) | 2012-08-21 | — | — | US | disclosed |
| US-8247372-B2 | Depsipeptides and their therapeutic use | UNIVERSITY OF SOUTHAMPTON (GB) | 2012-08-21 | — | — | US | disclosed |
| US-20100056434-A1 | Depsipeptides and Their Therapeutic Use | UNIVERSITY OF SOUTHAMPTON (GB) | 2010-03-04 | — | — | US | disclosed |
| US-20100056434-A1 | Depsipeptides and Their Therapeutic Use | UNIVERSITY OF SOUTHAMPTON (GB) | 2010-03-04 | — | — | US | disclosed |
| US-20100056434-A1 | Depsipeptides and Their Therapeutic Use | UNIVERSITY OF SOUTHAMPTON (GB) | 2010-03-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100056434-A1 | Depsipeptides and Their Therapeutic Use | HDAC11, HDAC1, HDAC6 | KLK5 3408/4885PSEN1 3445/4885PSEN2 4163/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.